PMCB (PharmaCyte Biotech) Change In Inventory : $0.00 Mil (TTM As of Jan. 2025)

View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Change In Inventory?

PharmaCyte Biotech's change in inventory for the quarter that ended in Jan. 2025 was $0.00 Mil. It means PharmaCyte Biotech's inventory stayed the same from Oct. 2024 to Jan. 2025 .

PharmaCyte Biotech's change in inventory for the fiscal year that ended in Apr. 2024 was $0.00 Mil. It means PharmaCyte Biotech's inventory stayed the same from Apr. 2023 to Apr. 2024 .

PharmaCyte Biotech's Total Inventories for the quarter that ended in Jan. 2025 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PharmaCyte Biotech Change In Inventory Historical Data

The historical data trend for PharmaCyte Biotech's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Change In Inventory Chart

PharmaCyte Biotech Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Change In Inventory

Get a 7-Day Free Trial

PharmaCyte Biotech Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

PharmaCyte Biotech Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PharmaCyte Biotech (NAS:PMCB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PharmaCyte Biotech's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

PharmaCyte Biotech's Inventory Turnover for the quarter that ended in Jan. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PharmaCyte Biotech's Inventory to Revenue for the quarter that ended in Jan. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

PharmaCyte Biotech Change In Inventory Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website

https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb	director	100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen	director	299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K	director
Carlos Trujillo	director, officer: CFO	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner	director, officer: Chairman, CEO, Pres and GC	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree	director, officer: Chief Science Officer	12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099